Form 8-K - Current report:
SEC Accession No. 0001628280-25-023154
Filing Date
2025-05-07
Accepted
2025-05-07 16:07:33
Documents
17
Period of Report
2025-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20250507.htm   iXBRL 8-K 37009
2 EX-99.1 vnda8-k572025exhibit991.htm EX-99.1 123217
7 vandaq32019earningsca_imag.jpg GRAPHIC 49643
8 vnda8-k572025graph.jpg GRAPHIC 62425
  Complete submission text file 0001628280-25-023154.txt   499957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20250507.xsd EX-101.SCH 2737
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20250507_def.xml EX-101.DEF 16088
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20250507_lab.xml EX-101.LAB 28702
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20250507_pre.xml EX-101.PRE 16826
19 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20250507_htm.xml XML 4265
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 25921355
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)